Pulmonary tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, most commonly affecting the lungs. Tuberculosis is treated with antibacterial drugs following a therapy schedule lasting six months. Drugs are mainly given by the oral route. Thus, TB is treated by a combination of several drugs. In the EU there is a request for optimizing the therapeutic management of TB disease, particularly in children, focusing on the appropriate dosing.Since the lung is the primary entrance for the mycobacterium, the interest in the management of TB by delivering drugs through the same gateway is well justified. The chapter turns its attention to the formulation of inhalation products that could be employed in several critical therapeutic and socio‐economical situations with expected greater efficacy in terms of the amount of drug deposited and local drug availability.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Formulation Strategies for Antitubercular Drugs by Inhalation|
|Data di pubblicazione:||2016|
|Appare nelle tipologie:||02.1 Contributo in volume (Capitolo, articolo)|